[HTML][HTML] Comparison of clinical outcomes following gefitinib and erlotinib treatment in non–small-cell lung cancer patients harboring an epidermal growth factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - Elsevier
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - europepmc.org
Background Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor …
SH Lim, JY Lee, JM Sun, JS Ahn… - Journal of Thoracic …, 2014 - snucm.elsevierpure.com
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - jto.org
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor …
SH Lim, JY Lee, JM Sun, JS Ahn… - JOURNAL OF …, 2014 - scholarworks.bwise.kr
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor …
SH Lim, JY Lee, JM Sun… - Journal of …, 2014 - mdanderson.elsevierpure.com
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor …
SH Lim, JY Lee, JM Sun, JS Ahn… - Journal of thoracic …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
[PDF][PDF] Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - core.ac.uk
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
[引用][C] Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - cir.nii.ac.jp
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell
Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either …
Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either …
[PDF][PDF] Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor …
SH Lim, JY Lee, JM Sun, JS Ahn… - Journal of Thoracic …, 2014 - scholar.archive.org
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …